Pharmacovigilance Steering Committee Chair, TransCelerate; Chief Safety Officer, Janssen
Dr. Paul Chang is the Chief Safety Officer at Janssen, the Pharmaceutical Companies of Johnson & Johnson. Paul is responsible for all aspects of patient safety and pharmacovigilance (PV), including medical safety assessment & risk management, safety operations, safety science & policy and International PV.
Paul joined Johnson & Johnson in 2006, and has held various leadership positions in both pharmaceutical and medical device sectors, including the Head of Cardiovascular, Metabolism and Internal Medicine Clinical Development at Janssen, Head of Clinical Research and Project Management at Cordis Corporation, and Head of Cardiovascular & Metabolism Medical Affairs at Janssen.
Prior to J&J, Paul held leadership positions including Vice President of CV and Immunology Global Clinical Research at Bristol-Myers Squibb; and Director of CV Clinical Research at Merck where he started his healthcare industry career.
Paul received his undergraduate degree at Columbia University and his M.D. degree from Yale University School of Medicine. He completed his Internal Medicine training at the New York Hospital / Cornell University Medical Center and his Cardiovascular Disease fellowship at Yale New Haven Hospital.
Paul is married with 3 children, and enjoys fly fishing in his spare time.